MedPath

Patient Care Needs and the Decision-Making Experience of Patients With Cancer and Family Caregivers Regarding Immunotherapy: A Qualitative and Quantitative Mixed Methods Study

Completed
Conditions
Supportive Care Needs
Immunotherapy
Registration Number
NCT05740800
Lead Sponsor
National Taiwan University Hospital
Brief Summary

Immunotherapy is currently a crucial cancer treatment option. Despite the development of new cancer treatment, patients and their family caregivers still experience complex psychological feelings and challenges about the effectiveness of immunotherapy, financial burden, and treatment related side effects which reflect the problems related to decision-making and the supportive care needs.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
184
Inclusion Criteria
  1. 20 years old and above.
  2. Patients diagnosed with cancer by a physician.
  3. The patient has a known condition and has received immunotherapy.
  4. Those who have received at least 1 time immunotherapy, including: receiving a single drug or immunotherapy combined with other treatment.
Read More
Exclusion Criteria
  1. Patients with mental illness.
  2. Confused and unable to communicate verbally or in writing to complete the research interviews.
  3. Those who are reluctant to accept interviews and participate in research surveys.

Family caregivers

Inclusion Criteria:

  1. 20 years old and above.
  2. Live with the patient and spend the most time caring for the patient.
  3. The primary family caregiver is identified by the patient.

Exclusion Criteria:

  1. Caregivers with mental illness.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Supportive Care Needs Survey1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Patients' and family caregivers' supportive care needs will be measured by Supportive Care Needs Survey(SCNS) .It is a 5-Point Likert Scale,higher scores mean more care needs.

Secondary Outcome Measures
NameTimeMethod
CollaboRATE scale and SURE scale1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Patients' and family caregivers' decision making process and conflict will be measured by CollaboRATE scale and SURE scale. CollaboRATE scale is a 10-Point Likert Scale (0-9), higher the score, the more effort you pay on this issues. SURE scale which base on Decisional Conflict Scale are 4 items,The question you agree that you can answer "YES" and got 1 point,if you not fit the description you have to answer "NO" and got 0 points,The lower the total score, the greater the decision conflict.

Physical and Psychological Symptoms Scale1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Patients' and family caregivers' physical and psychological symptoms will be measured by Physical and Psychological Symptom Scale.It use Numerical Rating Scale(VRS)0-10.It is a 11 Point Likert Scale(e. g. 0 is no pain; 10 is unbearable pain) .

Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT)1 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Patients' financial toxicity will be measured by COST-FACIT. It is a 5-Point Likert Scale (0-4),The higher the score for each question, the more often the problem occurs.

Common Terminology Criteria for Adverse Events (CTCAE) version 5.01 time points: From date of approaching patient until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.

Patients' immunotherapy side effects will be measured by CTCAE.The severity is divided into 5 grades, the higher the grade, the higher the severity.

Trial Locations

Locations (1)

National Taiwan University

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath